AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The pharma giant's drug combo is now just months away from potential U.S. approval for a type of liver cancer.

Here's What AstraZeneca's Recent FDA News Means for Shareholders

Sanofi

STERIS

Market downturns don't affect stocks equally.

3 Unstoppable Stocks That Are Higher Than Before the Market Correction

Although cancer screening and diagnosis was hit by the coronavirus pandemic, resulting advances in medical technology and greater diversity in clinical trials could help treatments in the future, an AstraZeneca executive said.

Cancer treatments may benefit from lessons of pandemic set-backs -AstraZeneca executive

AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.

AstraZeneca (AZN) Gets EU Nod for COVID-19 Booster Shot

Eli Lilly

Share buybacks and dividends among large drug makers reached a five-year high in 2021 as spending climbed to about $110 billion, according to an analysis by pharma consulting group Evaluate Vantage.

Eli Lilly and AstraZeneca Are the Lowest Spenders on Dividends, Buybacks

Eli Lilly and AstraZeneca Lowest Spenders on Dividends, Buybacks

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine cancer care with new data to be presented across its diverse and industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. A total of 18 approved and potential new medicines from AstraZeneca will be featured across more than 100 abstracts, including nine oral presentations and a plenary presentation of the DESTINY-Breast04 Phase III trial for

AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022

AstraZeneca's Covid-19 vaccine gets EU approval for third doses

AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.

AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies

Johnson & Johnson

Lockheed Martin

AT&T

Walmart

Each of these stocks to buy are low-beta stocks with attractive dividend yields to help endure a recession. The post 5 Stocks to Buy for the Coming Recession appeared first on InvestorPlace.

5 Stocks to Buy for the Coming Recession

Aviva PLC

Reckitt Benckiser Group PLC

The looming spectre of stagflation, the process where an economy is dogged by both low growth and high inflation and unemployment, is awakening like an embalmed mummy after a deep slumber. Although there has been a lot of press already this already, including some confident dismissals, nobody knows for sure whether the phenomenon last seen in the 1970s will creep back.

If stagflation emerges, buy AstraZeneca and Reckitt, avoid Aviva and BP says analyst

MUNICH--(BUSINESS WIRE)--Proteros biostructures GmbH (“Proteros”), an expert in integrated structure-based drug discovery, announces today an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) focused on the discovery and development of novel epigenetic drugs. The new multi-year agreement builds on an ongoing collaboration with AstraZeneca announced in June 2021, to include the development of small molecule inhibitors targeting a second cancer-associated epigenetic protein. U

Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca

CHENGDU, China and SEATTLE and LONDON , May 13, 2022 /PRNewswire/ -- BAILI-BIOPHARMACEUTICAL CO., LTD. ("Baili") and its wholly owned subsidiary, SystImmune, Inc ("SystImmune"), announced today that it has entered into a clinical trial collaboration and supply agreement with AstraZeneca (LSE :AZN) (STO: AZN) (NASDAQ : AZN) to evaluate the combination of Baili's cancer therapy, SI-B001, an EGFR x HER3 bispecific antibody, in combination with AstraZeneca's third-generation, irreversible epidermal growth factor receptor ("EGFR") TKI, TAGRISSO® (osimertinib), in a new Phase 2a study, sponsored and conducted by Baili, for patients with non-small cell lung cancer ("NSCLC").

Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer

Inovio Pharmaceuticals

Moderna

Pfizer

Is This Vaccine Stock in Trouble -- or Ready for a Rebound?

Biopharmaceutical stock AstraZeneca PLC (NASDAQ:AZN) settled around the $64.52 level on Friday, which also marks its $200 billion market cap as well as two prior highs in November 2021 and July 2020.

Biopharma Stock Could Soon Break Higher

These three pharma stocks each pay market-beating dividends to shareholders.

3 Top Biotech Stocks to Buy Right Now

Broadcom

Baidu

These fast-paced stocks are plain-as-day bargains.

3 Nasdaq 100 Stocks to Buy Hand Over Fist in May

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

After the Alexion maxi-acquisition, the company beat both revenue and EPS consensus. Premium pipelines deserve a premium valuation.

AstraZeneca: Our Next Growth Pick

AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.

AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates

AstraZeneca plc (LON: AZN) on Friday said vaccine contracts helped its Q1 financial results. Moving forward, however, it expects COVID-related sales to sink by 21% to 25%.

AstraZeneca CEO: ‘each of our businesses grew a lot in Q1'

AstraZeneca Plc's (NASDAQ: AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicines and several Vaxzevria contracts that are expected to complete the delivery by half.

AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

The Anglo-Swedish drugmaker reported sales of $11.4 billion, above the analyst consensus for $10.9 billion.

AstraZeneca Beats Estimates, but Warns Demand for Covid Vaccine Will Fade

AstraZeneca PLC (LSE:AZN) repeated its guidance for the full year after it reported forecast-beating results for the first quarter, boosted by sales of its diabetes drug and Covid-19 vaccine. The pharma company also announced plans to open a strategic research and development centre and new headquarters for its rare diseases subsidiary Alexion in Cambridge, Massachusetts.

AstraZeneca beats profit and revenue forecasts; to open new R&D site

AstraZeneca PLC said Friday that it expects sales of its Covid-19 medicines, including its vaccine, to decline by a low-to-mid twenties percentage during the year, but reported higher revenue in the first quarter on the back of previous vaccine contracts.

AstraZeneca revenue surges $11.39 billion, but sees COVID vaccine sales decline

News for AstraZeneca Stock (AZN)